| Code | CSB-RA007690MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Eltivutabart, targeting ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), also known as CD39. ENTPD1 is an ectoenzyme that catalyzes the sequential hydrolysis of extracellular ATP and ADP to adenosine monophosphate, playing a critical role in purinergic signaling and immune regulation. By converting pro-inflammatory ATP into immunosuppressive adenosine precursors, ENTPD1 creates an immunosuppressive microenvironment that can promote tumor immune evasion. Elevated ENTPD1 expression has been observed on regulatory T cells, tumor-infiltrating lymphocytes, and various cancer cells, making it an important target in immuno-oncology research.
Eltivutabart represents a novel therapeutic antibody designed to block ENTPD1 activity and restore anti-tumor immune responses. This biosimilar antibody provides researchers with a valuable tool for investigating ENTPD1-mediated immune suppression mechanisms, studying purinergic signaling pathways, and exploring combination immunotherapy strategies. It supports preclinical studies examining the role of CD39 in tumor progression, immune checkpoint regulation, and therapeutic resistance across various cancer models.
There are currently no reviews for this product.